AI research summary

LLY bull vs bear

The optimistic and cautious cases for Eli Lilly and Company, grounded in analyst targets, company information, and recent reporting.

High target

$1,500.00

Consensus

$1,341.63

Low target

$1,135.00

Wall Street

Buy

45 analyst ratings

The consensus Wall Street rating for Eli Lilly is 'Buy' based on 45 analyst opinions, with 33 recommending Buy, 9 recommending Hold, and 3 Sell ratings. There are no Strong Buy or Strong Sell recommendations, indicating moderate analyst confidence in the stock's prospects. The 12-month price targets range from $1,135.00 to $1,500.00, averaging $1,341.63, suggesting potential upside from current levels.

Bull case

What could go right

The most optimistic analysts expect the stock to reach as high as $1,500.00 within the next year. Eli Lilly's strong diabetes portfolio, including insulin products like Humalog and specialized treatments such as Jardiance and Trulicity, supports steady revenue growth. The company’s oncology lineup with drugs like Alimta and Verzenio addresses multiple cancer types, providing diversification. A recent significant development is the FDA clearance of a new Alzheimer's blood test developed jointly with Roche, potentially opening new markets in neurological diagnostics and treatment [3][4][5]. Management's guidance for fiscal 2026 revenue between $85 billion and $87 billion reflects confidence in growth prospects [2].

What supports this case

Robust diabetes drug portfolio including insulin products and differentiated therapies like Jardiance and Trulicity
Diverse oncology treatments covering multiple cancer indications such as Alimta and Verzenio
FDA approval of Roche and Eli Lilly's Alzheimer's blood test, expanding neurological diagnostics and treatment opportunities [3][4][5]
Management's strong revenue guidance for fiscal 2026 between $85 billion and $87 billion indicating expected financial growth [2]

Bear case

What could go wrong

On the cautious side, some analysts expect the stock could fall as low as $1,135.00 within the next year. Despite strong fundamentals, Eli Lilly's valuation is high with a price-to-earnings ratio around 41.8, which could pose a risk if growth slows or sentiment shifts. Recent stock price volatility, including a slip from a $1.1 trillion valuation and pullback from 52-week highs, suggests potential market concerns or profit taking [1]. Competition in key therapeutic areas like diabetes and oncology is intense, which could pressure market share and pricing. The company's heavy reliance on a few blockbuster drugs poses concentration risk if any face regulatory or competitive setbacks.

What could pressure the stock

High valuation with a P/E ratio near 42, raising risk if growth expectations are not met
Recent stock price slip from approximately $1,245 amid valuation cooling, indicating possible market concerns or profit taking [1]
Intense competition in diabetes and oncology drug markets potentially affecting market share and pricing

Balanced view

What to watch next

Investors should closely monitor Eli Lilly's ability to maintain growth in its diabetes and oncology franchises as detailed in its product lineup. The market reception and commercial rollout of the FDA-approved Alzheimer's blood test in collaboration with Roche will be critical to watch. Additionally, maintaining revenue growth close to the $85-$87 billion guidance for fiscal 2026 alongside valuation trends will be key indicators of the company’s performance potential. Competitive dynamics and regulatory developments could materially influence future outcomes.

Research

Sources

5 sources